Showing posts with label PET/CT. Show all posts
Showing posts with label PET/CT. Show all posts

Tuesday, November 1, 2022

AI of Coronary Calcium Accurately Predicts Adverse Cardiovascular Events

 A study published in the Journal of the American College of Cardiology (JACC) Cardiovascular Imaging reports that researchers found that AI algorithms can more rapidly and objectively determine coronary calcium score (CAC) in CT and PET images than physicians.  The model was trained using 9,543 CT scans from a cohort of 4,331 patients with major adverse cardiac events (MACEs) who underwent PET/CT imaging.  MACE risk stratification in four CAC score categories (0, 1-100, 101-400 and over 400).  The AI also performed well when studies were obtained from very-low-attenuation scans.  The authors concluded that AI CT scores predict risk similarly to CAC scores obtained by experienced operators from ECG gated CAC scans. 

Wednesday, October 8, 2014

Contrast-enhanced PET/CT, more accurate, in metastatic pancreatic cancer

Yoneyana et al in their study that was published in the EuropeanJournal of Radiology report on the accuracy of contrast-enhanced (CE) 18F-fluorodeoxyglucose (FDG)–positron emission tomography (PET)/computed tomography (CT) in the staging of pancreatic cancer.

A total of 95 patients with primary pancreatic cancer underwent 18F-FDG PET/CT examinations.  The diagnostic accuracy between non-CE PET/CT and CE PET/CT was compared using as a reference standard histology in 48 patients (51%) and an obvious progression in number or size of the lesions on follow-up CT examinations in 47 patients (49%). 

Invasion of duodenum (n = 20, 21%), mesentery (n = 12, 13%), and retroperitoneum (n = 13, 14%) was correctly diagnosed by both modalities.  The diagnostic accuracy of nodal metastases of the two modalities was similar with metastases correctly diagnosed by CE PET/CT in 38 patients (88%) and by non-CE PET/CT in 45 patients (87%). Using CE PET/CT, distant metastases, scalene node metastasis, and peritoneal dissemination were correctly diagnosed in 39 patients (91%), while interpretation based on non-CE PET/CT revealed distant metastasis, scalene node metastasis, and peritoneal dissemination in 42 patients (81%).  Therefore, the diagnostic accuracy of CE PET/CT was significantly higher than that of non-CE PET/CT (p < 0.05) in distant metastases, scalene node metastasis, and peritoneal dissemination.


The authors concluded that the addition of contrast in PET/CT studies allows for a more precise assessment of distant metastases, scalene node metastases, and peritoneal dissemination in patients with pancreatic cancer.